CIKS/Act1 Antibody
Rabbit Polyclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB |
---|---|
Primary Accession | O43734 |
Other Accession | AAG15407 |
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Calculated MW | 64666 Da |
Gene ID | 10758 |
---|---|
Application & Usage | Western blotting (0.5-4 µg/ml). However, the optimal conditions should be determined individually. The antibody detects the ~63 kDa human CIKS/Act1. Human placenta tissue lysate can be used as a positive control. |
Other Names | CIKS, ACT1, ACT-1, TRAF3IP2, C6orf4, C6orf5, C6orf6, RAF3-interacting protein 2, Nuclear factor NF-kappa-B activator 1; ACT1; Adaptor protein CIKS; Adapter protein CIKS |
Target/Specificity | CIKS/Act1 |
Antibody Form | Liquid |
Appearance | Colorless liquid |
Formulation | 100 µg (0.5 mg/ml) affinity purified rabbit anti-CIKS/Act1 polyclonal antibody in phosphate buffered saline (PBS), pH 7.2, containing 30% glycerol, 0.5% BSA, and 0.01% thimerosal. |
Handling | The antibody solution should be gently mixed before use. |
Reconstitution & Storage | -20 °C |
Background Descriptions | |
Precautions | CIKS/Act1 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | TRAF3IP2 (HGNC:1343) |
---|---|
Function | E3 ubiquitin ligase that catalyzes 'Lys-63'-linked polyubiquitination of target protein, enhancing protein-protein interaction and cell signaling (PubMed:19825828). Transfers ubiquitin from E2 ubiquitin-conjugating enzyme UBE2V1-UBE2N to substrate protein (PubMed:19825828). Essential adapter molecule in IL17A-mediated signaling (PubMed:19825828, PubMed:24120361). Upon IL17A stimulation, interacts with IL17RA and IL17RC receptor chains through SEFIR domains and catalyzes 'Lys-63'-linked polyubiquitination of TRAF6, leading to TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways (PubMed:19825828). |
Tissue Location | Widely expressed. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
CIKS (for connection to IKK and SAPK/JNK), also called Act1 (for NF-kB activator 1), is a novel protein that associates with and activates IKK (IkB kinase). CIKS/Act1 also activates ATF (activating transcription factor) and AP-1 (activator protein 1) thro µgh Jun kinase (JNK). CIKS/Act1 is ubiquitously expressed in human tissues.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.